Hypertrophic cardiomyopathy without outflow obstruction has long been a therapeutic dead end — a condition where the heart muscle thickens yet blocks no outflow tract, leaving physicians without a targeted pharmacological option. A Phase III randomized trial now challenges that stagnation, testing whether cardiac myosin inhibition can translate benefits seen in the obstructive form of this disease to the far more diagnostically elusive nonobstructive variant.
The NEJM-published trial evaluated aficamten, a selective cardiac myosin inhibitor, in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). Unlike obstructive HCM — where mavacamten and aficamten have already demonstrated measurable reductions in outflow gradient — nHCM presents without a mechanical obstruction to target, making functional improvement harder to demonstrate and attribute. The trial measured peak oxygen uptake (pVO₂) as its primary endpoint, capturing actual cardiopulmonary exercise capacity rather than a surrogate. Patient-reported outcomes and symptom burden were assessed as secondary endpoints, providing a multidimensional picture of clinical benefit across what appears to be a meaningful cohort.
The significance here extends well beyond a single molecule. Nonobstructive HCM accounts for roughly one-third of HCM cases and has historically been managed with beta-blockers and calcium channel blockers that blunt symptoms without addressing myocardial hypercontractility at the sarcomere level. Aficamten works upstream, modulating the number of actin-myosin cross-bridges to reduce excessive contractile force — a mechanism that could theoretically normalize energetics regardless of obstruction status. If replicated, this would represent a genuinely paradigm-shifting extension of targeted sarcomere therapy into a previously untreatable HCM subpopulation. Key limitations to watch: whether pVO₂ gains translate to hard outcomes like hospitalization or arrhythmia reduction, and whether dose titration safety data hold across longer follow-up. This is a major finding warranting close attention from cardiologists and high-risk patients alike.